Prospective Case Series of Cutaneous Adverse Effects Associated With Dabrafenib and Trametinib

The study investigated the cutaneous adverse effects of dabrafenib and trametinib in 14 patients with metastatic melanoma. All patients experienced at least one skin reaction, with the most common being papillomas (7/14), palmoplantar hyperkeratosis (5/14), alopecia (5/14), and seborrheic dermatitis-like eruptions (2/14). Three patients on trametinib developed acneiform eruptions, and one patient developed a keratoacanthoma-like squamous cell carcinoma. Side effects appeared as early as 2 weeks, with a mean onset of 9 weeks. The findings highlighted the necessity for awareness and management of these potential adverse effects.